The brokerage firm retained a ‘Buy’ call on the stock and raised the price target of Rs 2,780 from Rs 2,675. Lupin‘s stock declined 6 per cent Year-To-Date, reflecting concerns over expected US sales decline from a high base. The brokerage sees an upside risk to FY27 US sales guidance of USD 1.1–1.2 billion, estimating USD 1.25 billion.
